InterAx Biotech

Executive Summary

InterAx Biotech, a Swiss biotech founded in 2017, is pioneering a novel approach to GPCR drug discovery through its Deep Signal™ platform, which integrates mathematical modeling, machine learning, and experimental biology. This platform enables the rational design of small molecule and biologic therapeutics that modulate complex cellular signaling networks with improved efficacy and safety. By addressing the inherent complexity of GPCR signaling, InterAx aims to overcome traditional drug discovery challenges such as poor selectivity and high attrition rates. The company is building an internal pipeline targeting high-value GPCRs while also positioning its platform for strategic partnerships with pharmaceutical companies seeking to enhance their drug development programs. InterAx operates in the competitive GPCR therapeutics market, which represents a significant opportunity given that GPCRs are targets for ~34% of FDA-approved drugs. While still in the pre-clinical stage, the company's platform-based business model provides multiple value inflection points, including platform licensing, co-development agreements, and internal pipeline progression. InterAx has not disclosed significant funding rounds or partnerships to date, though the company's deep tech approach and experienced team in Basel position it well for future growth. Key near-term catalysts include a potential Series B financing round and the advancement of internal programs toward candidate nomination, which could validate the platform's drug design capabilities and attract strategic interest.

Upcoming Catalysts (preview)

• Q4 2026Series B funding round70% success
• H1 2027Initial platform partnership with pharma50% success
• H2 2027Nomination of development candidate for lead GPCR program60% success